Literature DB >> 26738514

Effectiveness of prognosticating pulmonary embolism using the ESC algorithm and the Bova score.

David Jimenez1, Jose Luis Lobo, Covadonga Fernandez-Golfin, Ana K Portillo, Rosa Nieto, Mareike Lankeit, Stavros Konstantinides, Paolo Prandoni, Alfonso Muriel, Roger D Yusen.   

Abstract

The prognostic value of the European Society of Cardiology (ESC) 2014 algorithm and the Bova score has lacked adequate validation. According to the ESC 2014 guidelines and the Bova score, we retrospectively risk stratified normotensive patients with PE who were enrolled in the PROTECT study. This study used a complicated course (which consisted of death from any cause, haemodynamic collapse, or recurrent PE) as the primary endpoint, and follow-up occurred through 30 days after the PE diagnosis. Of 848 patients, 37 % had a sPESI of 0 and 5 (1.6 %; 95 % confidence interval [CI], 0.5-3.7 %) experienced a complicated course. Of 143 patients with a sPESI of 0 points and negative computed tomographic pulmonary angiography (CTPA) for right ventricle (RV) dysfunction, three (2.1 %; 95 % CI, 0.4-6.0 %) experienced a complicated course. Four hundred seventy-eight (56 %) patients with a sPESI ≥ 1 had echocardiographic evidence of RV dysfunction or elevated troponin level or none, and 48 (10 %, 95 % CI, 7.5-13.1 %) experienced a complicated course. Fifty-seven (6.7 %) patients with a sPESI ≥ 1 had echocardiographic RV dysfunction and elevated troponin level, and 10 (17.5 %; 95 % CI, 8.8-29.9 %) experienced a complicated course, compared to 21.6 % (8 of 37 patients, 21.6 %; 95 % CI, 9.8-38.2 %) in Bova risk class III. In conclusion, the ESC 2014 prognostic algorithm is effective in the risk stratification of normotensive patients with PE. Use of CTPA did not improve the ability for identification of low-risk PE. Bova risk scoring did not significantly improve identification of intermediate-high risk PE.

Entities:  

Keywords:  Pulmonary embolism; biomarkers; clinical scores; echocardiography; prognosis

Mesh:

Year:  2016        PMID: 26738514     DOI: 10.1160/TH15-09-0761

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  6 in total

1.  Classification of high-risk with cardiac troponin and shock index in normotensive patients with pulmonary embolism.

Authors:  Savas Ozsu; Muge Erbay; Zerrin Gürel Durmuş; Tevfik Ozlu
Journal:  J Thromb Thrombolysis       Date:  2017-02       Impact factor: 2.300

2.  Comparison of two scores in predicting pulmonary embolism-related adverse events in intermediate-high-risk patients: a systematic review and meta-analysis.

Authors:  Carlo Bova; Ernesto Vigna; Massimo Gentile; Francesca Serena Pignataro
Journal:  Intern Emerg Med       Date:  2022-03-23       Impact factor: 5.472

3.  Validation of a fast prognostic score for risk stratification of normotensive patients with acute pulmonary embolism.

Authors:  Lukas Hobohm; Cecilia Becattini; Stavros V Konstantinides; Franco Casazza; Mareike Lankeit
Journal:  Clin Res Cardiol       Date:  2020-02-06       Impact factor: 5.460

4.  Implications of Abnormal Troponin Levels With Normal Right Ventricular Function in Normotensive Patients With Acute Pulmonary Embolism.

Authors:  Rosa Mirambeaux; Raphael Le Mao; Alfonso Muriel; Beatriz Pintado; Andrea Pérez; Diurbis Velasco; José Luis Lobo; Deisy Barrios; Raquel Morillo; Behnood Bikdeli; David Jiménez
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

5.  Simultaneous Pulmonary Artery Pressure and Left Ventricle Stroke Volume Assessment Predicts Adverse Events in Patients With Pulmonary Embolism.

Authors:  Hayaan Kamran; Essa H Hariri; Jean-Pierre Iskandar; Aditya Sahai; Ihab Haddadin; Serge C Harb; Joseph Campbell; Leben Tefera; Joseph M Delehanty; Gustavo A Heresi; John R Bartholomew; Scott J Cameron
Journal:  J Am Heart Assoc       Date:  2021-09-06       Impact factor: 5.501

Review 6.  Acute pulmonary embolism multimodality imaging prior to endovascular therapy.

Authors:  David Sin; Gordon McLennan; Fabian Rengier; Ihab Haddadin; Gustavo A Heresi; John R Bartholomew; Matthias A Fink; Dustin Thompson; Sasan Partovi
Journal:  Int J Cardiovasc Imaging       Date:  2020-08-30       Impact factor: 2.357

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.